tailieunhanh - SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy

SETD2 protects against genomic instability via maintenance of homologous recombination repair (HRR) and mismatch repair (MMR) in neoplastic cells. However, it remains unclear whether SETD2 dysfunction is a complementary or independent factor to microsatellite instability-high (MSI-H) and tumor mutational burden-high (TMB-H) for immunocheckpoint inhibitor (ICI) treatment, and little is known regarding whether this type of dysfunction acts differently in various types of cancer. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN